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TAKE HOME MESSAGE 
 
This meta-analysis shows that in high-altitude dwellers suffering from chronic mountain 
sickness pulmonary hypertension, while rare at rest, is frequent during daily activities.  
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Abstract 
 
Among the >140 million dwellers worldwide up to 10% suffer from chronic mountain 
sickness (CMS). Patients suffering from this debilitating problem often display increased 
pulmonary artery pressure (PAP) which may contribute to exercise intolerance and right 
heart failure. However, there is little information on the usual PAP in these patients.  
We systematically reviewed and meta-analyzed all data published in English or Spanish 
until June 2018 on echocardiographic estimations of PAP at rest and during mild 
exercise in CMS patients. 
Nine studies, comprising 287 participants fulfilled the inclusion criteria. At rest, the point 
estimate from meta-analysis of the mean systolic PAP was 28.0 mmHg [95% confidence 
interval (CI) 26.3, 29.6]. These values are 11% (+2.7 mm Hg) higher than those recently 
meta-analysed in apparently healthy high-altitude dwellers (J Appl Physiol 121:1151–9, 
2016). During mild exercise (50 W) the difference in mean systolic PAP between 
patients and high-altitude dwellers was markedly more accentuated (48.3 vs. 36.3 mm 
Hg) than at rest. 
These findings indicate that in patients with CMS PAP is moderately increased at rest, 
but markedly increased during mild exercise, which will be common with activities of 
daily living.  
 
 
 
 
 
INTRODUCTION 
 
An increase of pulmonary artery pressure is a hallmark of high-altitude exposure and, if 
pronounced, it may be associated with important morbidity and mortality. Worldwide 
more than 140 million people are living at high altitude of whom a substantial number 
are suffering from chronic mountain sickness (CMS) [1, 2]. For example, among Andean 
high-altitude dwellers, an estimated 5-10 % are suffering from this debilitating disease 
characterized by excessive erythrocytosis and arterial hypoxemia [2]. CMS patients 
often also display increased pulmonary artery pressure that is thought to contribute to 
exercise intolerance and right heart failure, which is common in these patients [3, 4]. 
There is, however, little information on the extent of the increase of pulmonary artery 
pressure in CMS.  
The advent of echocardiography as a reliable tool to noninvasively estimate and 
compare pulmonary artery pressure (PAP) between groups [5-7] allowed eliminating the 
restrictions related to the more precise, but invasive and often unavailable, gold 
standard measurements by right heart catheterization and permitted investigators to 
perform studies under field conditions. Since these studies generally comprise relatively 
few participants, the prevalence of PAP in high-altitude dwellers suffering from CMS 
remains ill-defined at present.     
To fill this gap, we systematically reviewed and meta-analysed all data published in 
English or Spanish on echocardiographic estimations of PAP and measurements of 
arterial oxygen saturation (SaO2) in high-altitude dwellers (>2500 m) suffering from 
CMS. Moreover, since there is evidence that in patients with CMS mild exercise during 
daily activities worsens pulmonary hypertension and contributes to the symptoms and 
long-term complications [3, 8] we also analysed echocardiographic studies of PAP and 
arterial oxygen saturation during mild exercise in patients with CMS and high-altitude 
dwellers.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
We conducted a systematic review and meta-analysis of studies reporting 
echocardiographic estimates of PAP and arterial oxygen saturation in CMS patients at 
rest and during exercise. Reviewing and reporting were performed according to the 
recommendations of Cochrane collaboration [9] and the PRISMA Statement [10] (see, 
Appendix 1, Table S1), respectively. 
 
Data Sources and Searches 
 
We searched the MEDLINE and EMBASE databases up to June 2018, using PubMed 
and Ovid platforms. We used free text words and specific thesaurus terms (MeSH in 
MEDLINE and EMTREE in EMBASE), including “pulmonary artery”, “pressure”, “altitude” 
and “altitude sickness”. We also examined the bibliographies of relevant articles to 
identify eligible studies missed by the database searches. (see Appendix 1) 
 
Study Selection 
 
We included articles that reported the mean value and standard deviation (or standard 
error) of PAP by Doppler echocardiography in patients with CMS, defined as 
erythrocytosis with haemoglobin concentration >21 g/dL in the presence of a normal 
pulmonary function and no history of working in the mining industry. We excluded small 
studies reporting data in <10 participants, case reports and studies reporting duplicate 
data. We first checked the abstracts of retrieved articles for eligibility and excluded 
ineligible studies at this stage. We then examined the full text of potentially eligible 
articles and depending on whether they met eligibility criteria or not, included or 
excluded articles. 
  
Data Extraction 
 
Two reviewers (RS, NB) extracted data, using a data extraction sheet developed and 
piloted for this review. The two reviewers extracted the mean, standard deviation (SD) or 
standard error (SE) of systolic PAP and, if reported, the mean, SD or SE of arterial 
oxygen saturation. In the five studies that also reported PAP and arterial oxygen 
saturation during mild exercise [3, 4, 8, 11, 12], data for CMS patients and (for 
comparison) for high-altitude dwellers were extracted.  
We used the right-ventricular-to-atrial pressure gradients as an estimate of systolic PAP. 
In most included studies, PAP derives from continuous wave Doppler sampling of the 
tricuspid regurgitation jet, using the simplified Bernoulli equation. In a few studies that 
reported mean PAP instead of systolic PAP, we used the following formula [13] to 
calculate systolic PAP:  
 
Systolic PAP= (mean PAP-2)/0.61.   
 
If atrial pressure had been added to the pressure gradient, we subtracted these 
estimates to obtain a comparable set of data for meta-analysis. 
In the study were cardiac output (CO) during exercise at 50 Watts was not directly 
reported, we calculated it according to the following formula: 
CO [L/min.] = stroke volume [ml] x heart rate [bpm] / 1000. 
Cardiac index (CI, L/min/m2) was calculated according to the following formula:  
CO / body surface area [m2] and pulmonary vascular resistance (PVR) was calculated 
using the following formula: PVR=(mPAP-PAWP)/CO, where pulmonary artery wedge 
pressure (PAWP) was estimated by left atrial pressure (LAP). 
We further extracted bibliographic details, the study location and its altitude, the number, 
gender, age and ethnicity of the study participants, and the number of participants 
excluded from the analysis. Discrepancies between the two reviewers were resolved by 
discussion and consultation with the senior authors (ME, US or SFR). 
 
Methodological and Reporting Quality 
 
We assessed methodological and reporting quality of studies using the following criteria: 
(i) Was recruitment procedure described?; (ii) Clear description of inclusion and 
exclusion criteria; (iii) Number of participants with missing data for variables of interest; 
(iv) Was the study population representative for the general population?; (v) Was the 
echocardiography performed according to established standards?; (vi) Were potential 
sources of bias addressed?  
 
Statistical Analysis 
 
We combined the data on systolic PAP and arterial oxygen saturation using random-
effects meta-analysis. We converted SD to SE by dividing the SD by the square root of 
the number of participants included in the analysis and  expressed results as mean 
values and 95% confidence intervals. We used univariate meta-regression models to 
identify factors that may have influenced PAP in people suffering from CMS. We 
included age, study altitude, arterial oxygen saturation, body mass index, and 
hemoglobin. We assessed heterogeneity between studies using  the I2 statistic and the 
Chi2 test. We used the statistical package STATA (version 11.2, Stata Corp., College 
Station, TX, USA) for all analyses.  
For the simulated distribution, we plotted normal distributions of systolic PAP and 
oxygen saturation at rest and during exercise for hypothetical populations with and 
without CMS, based on means and standard deviations of reported data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
Identification of Eligible Studies 
 
We identified a total of 267 articles. Figure 1 shows the flow of the selection of studies 
and the reasons for exclusion. 
Based on titles and abstracts we excluded 68 duplicates and 180 articles that did not 
meet inclusion criteria. We examined 19 full-text articles and excluded ten articles 
because they did not meet the inclusion criteria (<10 participants, comorbidities, high-
altitude exposure <1 yr).  
 
Characteristics of Included Studies 
 
Nine studies with a total of 262 participants, fulfilled the inclusion criteria. The mean age 
of the participants was 47 years and their number ranged from 55 participants [14] in the 
largest to 12 [15] in the smallest study (Table 1). All studies were performed between 
3,600 and 4,350 m in the Andes. All participants were men and had an indigenous 
Andean (Aymara or Quechua) background. Five studies, in addition to reporting data at 
rest also reported measurements during mild exercise. CMS patients and high-altitude 
dwellers were matched for age, socio-economic background and ethnicity. 
 
 
 
 
Methodological and Reporting Quality 
 
All studies provided a clear description of the eligibility criteria but due to missing or 
incomplete reporting, it was unclear whether participants were truly representative of the 
general CMS population. In all studies, echocardiography was performed according to 
the quality criteria of the European Association of Echocardiography [16] . Some, but not 
all studies addressed potential sources of bias (Table 2).  
 
Two studies reported a selection bias towards the inclusion of patients with mild to 
moderate disease [3, 14]. This may have resulted in an underestimation of the true 
magnitude of pulmonary hypertension and arterial oxygen desaturation in the present 
meta-analysis. One study used the same absolute workload for exercise in all 
participants and did not use a subjective assessment of exercise intensity [4]. Even 
though the percentage of the maximal heart rate during exercise was similar in CMS 
patients and controls, the possibility exists that differences in relative workload may have 
contributed to the large differences of exercise-induced pulmonary hypertension (and 
pulmonary interstitial fluid accumulation) between the two groups. Finally, in one study, 
haemoglobin concentration was slightly <21 g/l in some patients, because of bloodletting 
shortly before the time of study [11]. It is unlikely that the slightly lower haemoglobin 
concentrations altered pulmonary artery pressure, since isovolemic hemodilution has no 
detectable effect on vascular function in CMS patients [17]. 
 
 
 
Meta-analysis of PAP and Arterial Oxygen Saturation at rest 
 
In all studies, experienced echocardiographers performed the PAP measurements. The 
point estimate from meta-analysis of the mean systolic PAP at rest was 28 mmHg [95% 
confidence interval (CI) 26.28, 29.64] (Figure.2), with the reported mean values ranging 
from 25.0 to 34.3 mmHg. The point estimate of mean arterial oxygen saturation at rest 
was 84.3% [95% CI 82.9, 85.6] (Figure.3) and the reported mean values ranged from 
81.0% to 87.0%. Meta-regression analyses revealed positive relationships between PAP 
and study altitude (P=0.005) and haemoglobin (P=0.001) and a negative correlation 
between PAP and arterial oxygen saturation (P=0.005). No significant relationships 
existed between PAP and age (P=0.56) or body mass index (P=0.98). 
 
Meta-analysis of PAP and Arterial Oxygen Saturation during mild exercise (50W) 
 
Five studies also reported data on systolic PAP and arterial oxygen saturation (Figure 4) 
during mild exercise (50 W) in CMS patients (n=142) and high-altitude dwellers (n=125). 
The exercise-induced increase of PAP was almost 2-fold larger in CMS patients than in 
high-altitude dwellers (22.0 vs. 13.0 mm Hg, P=0.001, CMS vs controls). The point 
estimate of systolic PAP during mild exercise in CMS patients was significantly 
(P=0.001) higher [48.26 mmHg, 95% (CI) 44.76, 51.76] than in high-altitude dwellers 
[36.26 mm Hg, 95% (CI) 32.99, 39.53]. Average systolic PAP during mild exercise 
ranged from 45.0 to 56.6 mm Hg in CMS patients and from 33.0 to 39.8 mm Hg in high-
altitude dwellers. The point estimate of arterial oxygen saturation during exercise was 
considerably lower (P=0.0004) in CMS patients [82.1%, 95% (CI) 80.6, 83.7] than in 
controls [89.4%, 95% (CI) 88.5, 90.3)], and its mean values ranged from 79.0 to 84.9% 
in the patients and from 87.7 to 90.3% in the controls.    
Cardiac output during mild exercise was comparable in CMS patients and controls 
(9.4±1.1 vs. 9.2±0.9 L/min, p=0.80) whereas left atrial pressure was slightly, albeit 
significantly higher in the patients (10.1±0.7 vs. 9.2±0.3 mm Hg, p=0.0457). Calculated 
pulmonary vascular resistance at 50 W tended to be higher in the patients (2.7±0.3 vs. 
2.2±0.6 mm Hg/L/min, p=0.090), a tendency which disappeared after correction for the 
increased hematocrit according to reference [18]. 
  
In all meta-analyses the heterogeneity was between 60 and 85 %, which in all cases 
was significant (p-values between 0.04 and 0.0001). 
 
Simulated distribution of PAP and arterial oxygen saturation in CMS patients and high-
altitude dwellers. 
Figure 5 and 6 show simulated distribution curves of PAP and arterial oxygen saturation 
in CMS patients and high-altitude dwellers at rest and during mild exercise. Curves are 
shifted towards higher (PAP), respectively lower (arterial oxygen saturation) values in 
the patients.  
  
 
 
 
 
 
DISCUSSION 
 
Among the more than 140 million people living at high altitude, CMS represents a major 
health problem. In the Andes 5 to 10% of high-altitude dwellers suffer from this 
debilitating disease which is often associated with increased PAP that is thought to lead 
to substantial morbidity and mortality [1, 2]. However, the extent of this increase remains 
poorly defined. To provide such information, we performed a meta-analysis on 
echocardiographic estimations of PAP and arterial oxygen saturation 287 high-altitude 
dwellers suffering from CMS. Since PAP measurements at rest underestimate the 
values observed during daily activity [8], we also searched for measurements of PAP 
during mild exercise in the meta-analysed studies. [19]. The meta-analysis revealed 
mean systolic PAP and mean arterial oxygen saturation are roughly 11% higher and 7% 
lower, respectively, than those meta-analysed previously in high-altitude dwellers living 
at similar altitude. Mild exercise strikingly accentuates the differences of PAP and 
arterial oxygen desaturation between the two groups. Taken together, these findings 
suggest that in CMS patients the PAP increase appears sufficiently severe to cause 
symptoms and long-term sequels.  
 
The present data represent by far the largest dataset on PAP and arterial oxygen 
saturation in patients suffering from CMS. Echocardiography is the standard technique 
to assess PAP in high-altitude populations, since for ethical and logistic reasons invasive 
measurements are not feasible in population-based studies [19]. Echocardiographic 
estimations of PAP have been validated against invasive measurements at high altitude 
[5] with good agreement between invasive and non-invasive measurements [6, 20]. 
Moreover, agreement between echocardiographic and invasive measures of pulmonary 
pressures during exercise is good among patients with a high quality tricuspid 
regurgitation Doppler signal [21]. Finally, the accuracy of echocardiographic estimations 
of PAP may depend on the experience of the echocardiographer. It is important to note 
that experienced investigators having published extensively in the field performed the 
estimations of PAP in all the studies meta-analysed [13, 22-24]. Taking the current 
definitions of pulmonary hypertension as a mean PAP >25 (European Respiratory 
Society) [25] or >30 mmHg (high-altitude consensus) [2] the findings of our meta-
analysis (systolic PAP of 27.9 = mean PAP of 22 mmHg) indicate that in CMS patients 
living at high altitude (3,600-4,200 m) pulmonary hypertension at rest is rare. 
The high-altitude Consensus [2]  states that this limit holds true in the absence of 
excessive erythrocytosis, implying that an increased haematocrit may be a cause of 
falsely diagnosed pulmonary hypertension [26]. This effect, which could contribute to 
differences in pulmonary artery pressure between high-altitude populations showing 
different erythropoietic responses to ambient hypoxia, has however never been 
systematically quantified. Along the same lines, the effects of blood-letting as treatment 
of increased pulmonary artery pressure in CMS are controversial [27-31] and need to be 
re-examined in controlled prospective studies.  
An important strength of the present study is that we also meta-analysed PAP during 
exercise. There is evidence that PAP measurements at rest may greatly underestimate 
PAP values during daily activity in CMS patients. In turn, this might underestimate the 
potential consequences of increased PAP for long-term morbidity and mortality in this 
population [8]. To provide information on this important issue, we included in our meta-
analysis studies assessing PAP during mild exercise (50 W), which will be associated 
with many activities of daily living. Of note, all exercise studies were performed in the 
semi-recumbent position, a procedure suitable to obtain reliable and reproducible 
tricuspid regurgitation envelopes during exercise [7]. 
 
During mild exercise, the difference in mean systolic PAP between CMS patients and 
high-altitude dwellers was markedly greater (48.3 vs. 36.3 mm Hg) than the one meta-
analysed previously at rest (28.0 vs. 25.0 mm Hg, CMS vs. controls) [19]. Indeed, in 
CMS patients mean PAP during mild exercise at 50 W (34.5 mm Hg, 95% CI, 32.4, 36.6) 
is above the recently suggested definition of exercise-induced pulmonary hypertension 
(mean PAP >30 mm Hg) [32], whereas in high-altitude dwellers mean PAP remains 
below this suggested cut-off value (27.2 mm Hg 95% CI 25.2, 29.2). There is consensus 
emerging to define exercise-induced pulmonary hypertension by a mean PAP >30 mm 
Hg at a cardiac output <10 L/min and a total pulmonary resistance >3 Wood units, in the 
absence of pulmonary hypertension at rest [32]. The present meta-analysis 
demonstrates that CMS patients fulfil two of these three criteria already at mild exercise. 
It is likely that many of them will fulfil all three criteria at maximal exercise. In line with 
this speculation, in the study of Groepenhoff et al. [33], we estimated a pulmonary 
vascular resistance of roughly 3.7 Wood units in CMS patients at maximal exercise. 
 
Of note, in disease states predisposing to pulmonary hypertension, exercise-induced 
pulmonary hypertension is a well-established cause of decreased exercise capacity, 
precedes the development of manifest pulmonary hypertension at rest in a proportion of 
patients and is associated with decreased life expectancy [32]. Several mechanisms 
may increase PAP in CMS. Pulmonary resistive vessels are less distensible in CMS 
patients than in healthy highlanders, probably because of vascular remodeling [8, 33], 
which is also detectable in the systemic circulation [17]. Moreover, exaggerated 
sympathetic activation [34] in conjunction with increased oxidative-nitrosative stress and 
decreased nitric oxide bioavailability [35, 36] may also facilitate pulmonary 
vasoconstriction. Finally, exercise-induced arterial oxygen desaturation was 
considerably more severe in the patients than in the control subjects (82.1 vs. 89.4 %).  
 
Collectively, these data strengthen the concept that in patients with CMS, 
measurements at rest markedly underestimate pulmonary hypertension and arterial 
oxygen desaturation during daytime activity. Interestingly, recent data show that sleep 
disordered breathing and nocturnal hypoxemia are more severe in CMS patients than in 
control subjects [12] and associated with pulmonary vascular dysfunction. It appears 
therefore possible that daytime measurements of PAP at rest also underestimate 
differences in PAP between CMS and high-altitude dwellers during sleep. In line with 
this speculation, invasive measurements of PAP in patients with obstructive sleep 
apnoea showed a marked progressive increase of PAP during the night [37]. 
 
All studies meta-analysed here were performed in Andean high-altitude dwellers. This 
may be related, at least in part, to the fact that the prevalence of CMS appears to be 
considerably higher in Andean than in Tibetan or African high-altitude dwellers [38]. 
Genetic studies provide evidence for differences in the evolutionary adaptation to high 
altitude between Andean, Tibetan and Ethiopian high-altitude populations [39]. These 
differences may have resulted in different regulation of the pulmonary circulation and 
may contribute to differences in PAP between high-altitude populations. It would be 
important to assess PAP in CMS patients of other than Andean origin.  
We used meta-regression models to identify factors that may have influenced PAP in 
CMS patients. We found that significant positive relationships existed between PAP and 
study altitude and haemoglobin concentration. Moreover, a significant negative 
relationship existed between PAP and arterial oxygen saturation. The significant 
relationship between study altitude and PAP (and arterial O2 saturation) also indicates 
that differences in study altitude explain, at least in part, the heterogeneity of the studies 
meta-analysed. Other reasons for the heterogeneity might be differences in CMS 
severity between studies or other unreported differences between study populations. 
 
The present data represent by far the largest dataset on PAP and arterial oxygen 
saturation at rest and during mild exercise in patients with CMS and high-altitude 
dwellers. However, the number of subjects remains relatively small and is limited to 
Andeans. Additional studies assessing PAP and arterial oxygen saturation at rest and 
during mild exercise in CMS patients living in the Andes and, importantly, in other high-
altitude regions of the world, are urgently needed. Finally, one should keep in mind that 
echocardiographic measurements of PAP, while highly accurate for population studies, 
are inappropriate for diagnostic decisions in individuals, because of their lack of 
precision.    
 
To conclude, this is the first systematic review and meta-analysis of studies reporting 
echocardiographic estimates of PAP and measurements of arterial oxygen saturation in 
high-altitude dwellers suffering from CMS. The data indicate that in CMS patients, mean 
systolic PAP at rest is roughly 3 mm Hg higher and arterial oxygen saturation 6 % lower 
than the values previously meta-analysed in high-altitude dwellers [19], but PAP at rest 
does not fulfil the current criteria for pulmonary hypertension. Importantly, mild exercise 
expected to be frequently associated with daily activity markedly accentuates the 
difference in PAP between patients and controls. Exercise-induced pulmonary 
hypertension may cause symptoms and long-term sequelae in high altitude dwellers.  
The exaggerated increase of PAP during exercise induces interstitial fluid accumulation 
in the lung [4] and may represent a cause of exertional dyspnea frequently encountered 
in CMS patients. Moreover, exercise-induced pulmonary hypertension, however 
measured, has been shown to be of diagnostic and/or prognostic relevance in mitral 
valve disease [40], aortic stenosis [41], heart failure [42], systemic sclerosis [43-45], 
chronic obstructive pulmonary disease [46] and symptomatic patients after pulmonary 
endarterectomy [47]. Prospective studies are urgently needed examining whether similar 
long-term sequelae are present CMS patients. 
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Table 1. Characteristics of included studies 
First author (year) 
No. of 
Participants* 
Mean (SD) 
age 
(years) 
Mean (SD) 
Hb (g/dL) 
Mean (SD) 
Htco (%) 
Study location (country) Altitude (m) Ethnicity 
Vargas (2006)[48] 
30 22.3 (4.3) 19.5 (0.7) - La Paz - Bolivia 3600 Aymara 
28 46.7 (7.1) 24 (2.3) - La Paz - Bolivia 3600 Aymara 
Maignan (2009)[14] 55 45 (10) 23.1 (1.6) - Cerro Pasco - Perú 4300 Quechua 
Stuber (2010)[8] 
30 47 (13) 
21.5 (1.7) 66 
La Paz, El Alto - 
Bolivia 3600 Aymara 
Pratali (2012)[4] 15 54 (9) 21.7 (1.3) 66 La Paz - Bolivia 3600 Aymara 
Groepenhoff (2012)[33] 13 50 (10.8) 24 (3.6) - Cerro Pasco - Perú 4350 Quechua 
Pratali (2013)[3] 46 51 (10) 21.5 (2) 63.3 La Paz - Bolivia 3600 Aymara 
Dedobbeleer (2015)[15] 12 51 (10) 24 (2) - Cerro Pasco - Perú 4350 Quechua 
Brenner (2015)[11] 35 52.4 (11.9) 21.6 (2.1) 62.5 La Paz - Bolivia 3600 Aymara 
Rexhaj (2016)[12] 23 52.8 (9.8) 21.7 (1.3) 66.9 La Paz - Bolivia 3600 Aymara 
* All participant are men; Hb = Hemoglobin; Htco = Hematocrit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Assessment of methodological quality of included studies 
Study 
Was recruitment 
procedure 
described? 
Clear description of 
inclusion/exclusion 
criteria 
Number of 
participants 
with missing 
data for 
variables of 
interest (%) 
Was the study 
population 
representative for 
the general 
population? 
Was 
Echocardiography 
perform reliably? 
Were 
potential 
sources of 
bias 
addressed? 
Vargas 2006 no yes unclear unclear yes no 
Maignan 2009 no yes 18 (32) unclear yes yes 
Stuber 2010 no yes 1 (3.3) unclear yes yes 
Pratali 2012 no yes unclear unclear yes yes 
Groepenhoff 2012 no yes unclear unclear yes no 
Pratali 2013 yes yes 3 (6.5) unclear yes yes 
Dedobbeleer 2015 no yes unclear unclear yes no 
Brenner 2015 yes yes unclear unclear yes unclear 
Rexhaj 2016 unclear yes 3 (13) unclear yes no 
 
 
                                    
 
 
 
 
 
 
 
 
 
FIGURE LEGEND 
 
Figure 1.  Flow of information through the different phases of systematic review. n, 
Number of the studies. 
 
Figure 2. Meta-analysis of mean systolic pulmonary artery pressure at rest and its 95% 
confidence interval (CI) in high-altitude dwellers suffering from CMS.  
 
Figure 3.  Meta-analysis of mean arterial oxygen saturation at rest and its 95% CI in 
CMS patients. 
 
Figure 4. Meta-analysis of mean systolic pulmonary artery pressure and mean arterial 
oxygen saturation during mild exercise (50W) and their 95% confidence interval (CI) in 
high-altitude dwellers (Panels A and C) and CMS patients (panels B and D).  
 
Figure 5. Predicted distribution of mean systolic pulmonary artery pressure in high-
altitude dwellers and CMS patients, at rest and during mild exercise. 
 
Figure 6. Predicted distribution of mean arterial oxygen saturation in high-altitude 
dwellers and CMS patients, at rest and during mild exercise. 
 
 
  
  
Appendix 1 
 
Table S1. PRISMA checklist 
 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
1 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
4 
Objectives  4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
4-5 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
- 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) 
and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
5-6 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.  
Appendix 
1, Table S1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, 
included in systematic review, and, if applicable, included in the 
meta-analysis).  
5-6 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
6-7 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
7 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used 
in any data synthesis.  
7 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference 
in means).  
7-8 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of 
studies, if done, including measures of consistency (e.g., I
2
) for 
each meta-analysis.  
7-8 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
- 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating which 
were pre-specified.  
8 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.  
8 - Figure 1 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and provide 
the citations.  
8-9, 22 
Table 1 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any 
outcome level assessment (see item 12).  
9, 23 
Table 2 
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention group 
(b) effect estimates and confidence intervals, ideally with a forest 
plot.  
- 
Synthesis of 
results  
21 Present the main results of the review. If meta-analyses are 
done, include for each, confidence intervals and measures of 
consistency. 
10-11 
Figures 
2, 3, 4 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies 
(see Item 15).  
- 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
11 
Figure 5 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence 
for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
11-14 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), 
and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
14-15 
Conclusions  26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.  
15 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other 
support (e.g., supply of data); role of funders for the systematic 
review.  
16 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097   
 
 
 
 
 
 
Search Strategy 
 
We ran the following search strategy in PubMed until June 2018: 
 
1. “pulmonary artery” [MeSH Terms] 
OR 
2. “pulmonary artery” [All Fields]  
OR 
3. “pulmonary” [All Fields] AND ”artery” [All Fields] 
OR 
4.  “pulmonary artery” [Title/Abstract] 
 
5. 1 OR 2 OR 3 OR 4 
 
6. “blood pressure” [MeSH Terms] 
OR 
7. “blood pressure” [All Fields] 
OR 
8. “pressure” [MeSH Terms] 
OR 
9. “pressure” [All Fields] 
 
10. 6 OR 7 OR 8 OR 9 
 
11. 5 AND 10 
 
12. “pulmonary hypertension” [MeSH Terms] 
OR 
13. “pulmonary hypertension” [All Fields] 
OR 
14. “pulmonary hypertension”  [Title/Abstract] 
 
15. 12 OR 13 OR 14 
 
16. 11 OR 15 
 
17. “chronic” [All Fields] 
OR 
18. “chronic” [Title/Abstract] 
 
19. 17 OR 18 
 
20. “altitude sickness” [MeSH Terms] 
OR 
21. “altitude sickness” [All Fields] 
OR 
22. “altitude” [All Fields] AND ”sickness” [All Fields] 
OR 
23. “altitude sickness” [Title/Abstract] 
OR 
24. “mountain sickness” [All Fields] 
OR 
25. “mountain” [All Fields] AND ”sickness” [All Fields] 
OR 
26. “mountain sickness” [Title/Abstract] 
 
27. 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 
 
28. 19 AND 27 
 
29. 16 AND 28 
 
We ran the following search strategy in EMBASE until June 2018: 
 
1. chronic mp. 
2. altitude sickness mp. or exp altitude disease/ 
3. mountain sickness mp. 
4. chronic mountain sickness mp. 
5. monge’s disease mp. 
6. 1 and 2 
7. 1 and 3 
8. 4 or 5 or 6 or7 
9. exp lung artery pressure/ or  lung artery pressure mp. or exp pulmonary artery/ 
10. pulmonary hypertension mp. or exp pulmonary hypertension/ 
11. systolic pulmonary artery mp. 
12. elevated pulmonary artery pressure mp 
13. 9 or 10 or 11 or 12 
14. high altitude mp. or exp altitude/ 
15. 8 and 13 and 14 
 
  
 
 
 


 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
